Skip to content

Levomilnacipran

Serotonin and Norepinephrine Reuptake Inhibitor — NERVOUS SYSTEM

Also known as: fetzima, levomilnacipran HCl, levomilnacipran hydrochloride

OfpFDA approvedATC N06AX28

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Levomilnacipran is an ofp drug in the Serotonin and Norepinephrine Reuptake Inhibitor class catalogued in DrugCentral. It was first approved by the FDA in 2013. Its mechanism of action is classified as Norepinephrine Uptake Inhibitors and Serotonin Uptake Inhibitors. DrugCentral lists 5 molecular targets, including Slc6a4, SLC6A4 and SLC6A2. Recorded indications include Major depressive disorder.

  • Approval status: ofp (first approved 2013 by the FDA).
  • Drug class: Serotonin and Norepinephrine Reuptake Inhibitor.
  • Mechanism of action: Norepinephrine Uptake Inhibitors; Serotonin Uptake Inhibitors.
  • Molecular targets: Slc6a4, SLC6A4, SLC6A2 and SLC6A3 (5 listed in DrugCentral).
  • Indications: Major depressive disorder.
  • ATC code: N06AX28 (Other antidepressants).
  • Molecular formula: C15H22N2O; molecular weight 246.35 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Major depressive disorder

Contraindications (1)

  • Angle-closure glaucoma

Mechanism & targets

Mechanism of action (MoA)Norepinephrine Uptake Inhibitors; Serotonin Uptake Inhibitors
Established pharmacologic classSerotonin and Norepinephrine Reuptake Inhibitor

Molecular targets (5)

TargetGeneActionActivity
Sodium-dependent serotonin transporterSlc6a4unknownKi 8.07
Sodium-dependent serotonin transporterSLC6A4inhibitorKi 7.95
Sodium-dependent noradrenaline transporterSLC6A2inhibitorKi 7.04
Sodium-dependent dopamine transporterSLC6A3unknownIC50 5.49
Glutamate NMDA receptorGrin1|Grin2a|Grin2b|Grin2c|Grin2d|Grin3b|Grin3aunknownIC50 5.20

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2013-07-25FDA—FOREST LABS INC

ATC classification

ATC codeTherapeutic hierarchy
N06AX28NERVOUS SYSTEM › PSYCHOANALEPTICS › ANTIDEPRESSANTS › Other antidepressants

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Blepharospasm696.0
Taste disorder604.5
Epilepsy456.7
Infusion site reaction440.7
Gastrooesophageal reflux disease404.8
Back injury342.2
Memory impairment298.4
Onychomadesis291.0
Peripheral venous disease288.4
Breast cancer stage III286.3
Product quality issue247.3
Paraesthesia240.7

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Levomilnacipran is on its molecule page.

Molecular formulaC15H22N2O
Molecular weight246.35 g/mol
CAS number96847-54-0
InChIKeyGJJFMKBJSRMPLA-DZGCQCFKSA-N
PubChem CID6917779
CCN(CC)C(=O)[C@]1(C[C@H]1CN)C1=CC=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Levomilnacipran used for?

DrugCentral lists the following indications for Levomilnacipran: Major depressive disorder.

How does Levomilnacipran work?

Levomilnacipran is classified as Norepinephrine Uptake Inhibitors and Serotonin Uptake Inhibitors; its molecular targets in DrugCentral include Slc6a4, SLC6A4 (inhibitor), SLC6A2 (inhibitor) and SLC6A3.

When was Levomilnacipran first approved?

Levomilnacipran was first approved by the FDA in 2013.

What drug class does Levomilnacipran belong to?

Levomilnacipran is in the Serotonin and Norepinephrine Reuptake Inhibitor class.

What is the chemical formula of Levomilnacipran?

Levomilnacipran has the molecular formula C15H22N2O and a molecular weight of 246.35 g/mol.

Browse: all drugs starting with L · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusOFP
First approval2013-07-25
AgencyFDA
Targets5
Indications1
FormulaC15H22N2O
DrugCentral ID4864
Interactive profile